Results: 4

1.
Figure 1

Figure 1. From: A Phase I Study of Aromatic -Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

Changes in UPDRS scores. Absolute changes in scores from baseline to 6 months for individual patients. OFF, off-medication state; ON, on-medication state; UPDRS, Unified Parkinson's Disease Rating Scale.

Shin-ichi Muramatsu, et al. Mol Ther. 2010 September;18(9):1731-1735.
2.
Figure 4

Figure 4. From: A Phase I Study of Aromatic -Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

FMT-PET images. Axial images at the level of the putamen are shown before and 24 weeks after gene therapy for all six patients. Increased FMT uptake persisted until 96 weeks in two patients. The 4-week images are not shown because they are similar to the 24-week images. FMT, 6-[18F]fluoro--m-tyrosine; PET, positron emission tomography.

Shin-ichi Muramatsu, et al. Mol Ther. 2010 September;18(9):1731-1735.
3.
Figure 2

Figure 2. From: A Phase I Study of Aromatic -Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

Evaluation of patients' diaries and daily doses of levodopa equivalents. For each 30-minute interval throughout the day, the patients recorded whether they were mobile (ON), immobile (OFF), or asleep. They also recorded the time with troublesome dyskinesias (Dyskinesia). The graph shows the percentage of hours in a day spent in each condition at baseline and at 6 months. The numbers on the bars indicate the mean daily doses of levodopa equivalents (mg). OFF, off-medication state; ON, on-medication state.

Shin-ichi Muramatsu, et al. Mol Ther. 2010 September;18(9):1731-1735.
4.
Figure 3

Figure 3. From: A Phase I Study of Aromatic -Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

Short-duration response to levodopa. Comparison of short-duration response to levodopa before (blue) and after gene therapy (brown) in three patients (A-4, A-5, and A-6). Patients took 100 mg of levodopa with 25 mg benserazide orally after 20 hours without dopaminergic medication. Values represent means and SE of three trials. Upper panels: plasma levodopa levels; lower panels: Unified Parkinson's Disease Rating Scale motor scores. *P < 0.05.

Shin-ichi Muramatsu, et al. Mol Ther. 2010 September;18(9):1731-1735.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk